In conclusion, our study provides mechanistic insights into the oncogenic effect of CLTC, and understanding of the SP1/CLTC/TFG axis serves a novel therapeutic strategy for patients with osteosarcoma. This evidence concerns the gene CLTC and osteosarcoma.